Company Overview and News

83
Jane's June Dividend Increases And Income - Retirement Accounts

2018-07-19 seekingalpha
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO IRET.PR DUKH GD IRET.PRC TRV IRET.PRB MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM IRET.PRCL RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL

5
BNS / Bank of Nova Scotia (Halifax, NS) FORM 10-D

2018-07-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BNS

51
Don't Sell Axon Enterprise - Cramer's Lightning Round (7/11/18)

2018-07-12 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, July 11.
SGEN UA PG NKE AMZN BNS ROKU UAA CSCO AAXN BNS

5
Banco Bilbao Divests 68% Share in BBVA Chile to Scotiabank

2018-07-10 zacks
Banco Bilbao Vizcaya Argentaria (BBVA - Free Report) recently closed a deal with Canada-based Bank of Nova Scotia (BNS - Free Report) , under which the former sold 68.19% of its shareholding in Banco Bilbao Vizcaya Argentaria, Chile, (BBVA Chile) to the latter. Moreover, the sale included Banco Bilbao’s stake in other Chilean subsidiaries which support the functioning of BBVA Chile. Notably, acquiring the majority stake in BBVA Chile now makes Bank of Nova Scotia the fourth largest bank in Chile.
BMO BNS BCH BMO BVA BNS

5
BRIEF-BBVA Completes Sale Of BBVA Chile to Bank Of Nova Scotia

2018-07-09 reuters
* SAID ON FRIDAY HAS COMPLETED SALE OF ITS STAKE IN BBVA CHILE TO THE BANK OF NOVA SCOTIA
BNS BNS

5
June 2018 Portfolio Update

2018-07-06 seekingalpha
As a dividend growth investor (DGI), I am driven to keep track of both my inflows and outflows. Increases in investment income represent one measure to assess whether I am winning or losing the game of money. While I have been diligent to track my progress on a quarterly and annual basis over the past few years, through 2018 I have also been providing monthly income updates.
BNS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BNS / Bank of Nova Scotia (Halifax, NS) on message board site Silicon Investor.

Bank of Nova Scotia Split
CUSIP: 064149107